These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15329041)

  • 41. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
    Lanza F; Goff J; Scowcroft C; Jennings D; Greski-Rose P
    Am J Gastroenterol; 1994 Aug; 89(8):1191-200. PubMed ID: 8053433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine.
    Swarbrick ET; Gough AL; Foster CS; Christian J; Garrett AD; Langworthy CH
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):431-8. PubMed ID: 8804870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial].
    Petite JP; Slama JL; Licht H; Lemerez M; Coste T; Andrieu J; Grimaud JC; Julien H; Dupuis J; Sallerin V
    Gastroenterol Clin Biol; 1993; 17(5):334-40. PubMed ID: 8349067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determining the optimal dose of lansoprazole injection by 24-hour intragastric pH monitoring.
    Sugiyama M; Aoki T; Matsuo Y
    J Clin Gastroenterol; 1995; 20 Suppl 2():S14-6. PubMed ID: 7594331
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
    Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
    Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
    Campbell DR; Haber MM; Sheldon E; Collis C; Lukasik N; Huang B; Goldstein JL
    Am J Gastroenterol; 2002 Sep; 97(9):2208-14. PubMed ID: 12358234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
    Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ
    N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
    Lai KC; Lam SK; Chu KM; Wong BC; Hui WM; Hu WH; Lau GK; Wong WM; Yuen MF; Chan AO; Lai CL; Wong J
    N Engl J Med; 2002 Jun; 346(26):2033-8. PubMed ID: 12087138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD; Wilde MI
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A clinical trial of lansoprazole in the treatment of duodenal ulcer].
    Pei Y; Wang B; Chen S
    Zhonghua Nei Ke Za Zhi; 1995 Sep; 34(9):606-8. PubMed ID: 8697927
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lansoprazole: in the management of gastroesophageal reflux disease in children.
    Scott LJ
    Paediatr Drugs; 2003; 5(1):57-61; discussion 62. PubMed ID: 12513106
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
    Earnest DL; Dorsch E; Jones J; Jennings DE; Greski-Rose PA
    Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lansoprazole: a proton pump inhibitor.
    Garnett WR
    Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lansoprazole for maintenance of remission of erosive oesophagitis.
    Freston JW; Jackson RL; Huang B; Ballard ED
    Drugs; 2002; 62(8):1173-84. PubMed ID: 12010078
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
    Langtry HD; Wilde MI
    Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM; Prakash A; Faulds D; Lamb HM
    Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose aspirin: protection from the panacea.
    Guda N; Vakil N
    Am J Gastroenterol; 2002 Dec; 97(12):3202-3. PubMed ID: 12492214
    [No Abstract]   [Full Text] [Related]  

  • 59. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Studies of various administration methods for lansoprazole injection using 24-hour intragastric pH monitoring.
    Inoue M; Nakamura M
    J Clin Gastroenterol; 1995; 20 Suppl 2():S17-21. PubMed ID: 7594332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.